HMPL 760
Alternative Names: HMPL-760Latest Information Update: 08 Jun 2023
At a glance
- Originator HUTCHMED
- Class Antineoplastics; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Preclinical B-cell lymphoma
Most Recent Events
- 14 Apr 2023 Preclinical trials in B-cell lymphoma in China (PO) prior to April 2023
- 14 Apr 2023 Pharmacodynamics data from the preclinical studies in B cell lymphoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 31 Dec 2022 HUTCHMED has patent protection for HMPL 760 in USA and pending patents in China, USA, Europe and Japan